| The suitability of oral diacetylmorphine in treatment-refractory patients with heroin dependence: a scoping review MLF Martins, EA Wilthagen, E Oviedo-Joekes, JH Beijnen, N de Grave, ... Drug and alcohol dependence 227, 108984, 2021 | 19 | 2021 |
| The neuroprotective action of amidated-kyotorphin on amyloid β peptide-induced Alzheimer’s disease pathophysiology RF Belo, MLF Martins, L Shvachiy, T Costa-Coelho, C de Almeida-Borlido, ... Frontiers in Pharmacology 11, 985, 2020 | 12 | 2020 |
| P-glycoprotein (ABCB1/MDR1) controls brain penetration and intestinal disposition of the PARP1/2 inhibitor niraparib ML F. Martins, NHC Loos, S Mucuk, D de Jong, MC Lebre, H Rosing, ... Molecular pharmaceutics 18 (12), 4371-4384, 2021 | 8 | 2021 |
| ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability NHC Loos, IA Retmana, W Li, MLF Martins, MC Lebre, RW Sparidans, ... Pharmacological Research 178, 106137, 2022 | 7 | 2022 |
| ABCB1 and ABCG2 restrict brain and testis accumulation and, alongside CYP3A, limit oral availability of the novel TRK inhibitor selitrectinib W Li, RW Sparidans, MLF Martins, M El-Lari, MC Lebre, O van Tellingen, ... Molecular Cancer Therapeutics 20 (6), 1173-1182, 2021 | 7 | 2021 |
| Organic anion-transporting polypeptide 2B1 knockout and humanized mice; insights into the handling of bilirubin and drugs W Li, D Iusuf, RW Sparidans, E Wagenaar, Y Wang, DR de Waart, ... Pharmacological Research 190, 106724, 2023 | 5 | 2023 |
| Drug transporters ABCB1 (P-gp) and OATP, but not drug-metabolizing enzyme CYP3A4, affect the pharmacokinetics of the psychoactive alkaloid ibogaine and its metabolites ML F. Martins, P Heydari, W Li, A Martínez-Chávez, N Venekamp, ... Frontiers in Pharmacology 13, 855000, 2022 | 4 | 2022 |
| Development and validation of a UPLC-MS/MS method with a broad linear dynamic range for the quantification of morphine, morphine-3-glucuronide and morphine-6-glucuronide in … P Heydari, MLF Martins, H Rosing, MJX Hillebrand, A Gebretensae, ... Journal of Chromatography B 1166, 122403, 2021 | 4 | 2021 |
| Enhancement of the oral availability of Cabazitaxel using the cytochrome P450 3A (CYP3A) inhibitor ritonavir in mice NHC Loos, MLF Martins, D de Jong, MC Lebre, M Tibben, JH Beijnen, ... Molecular Pharmaceutics 20 (5), 2477-2489, 2023 | 3 | 2023 |
| Interplay of OATP1A/1B/2B1 uptake transporters and ABCB1 and ABCG2 efflux transporters in the handling of bilirubin and drugs W Li, RW Sparidans, Y Wang, MLF Martins, DR de Waart, O van Tellingen, ... Biomedicine & Pharmacotherapy 175, 116644, 2024 | 1 | 2024 |
| Coadministration of ABCB1/P-glycoprotein inhibitor elacridar improves tissue distribution of ritonavir-boosted oral cabazitaxel in mice NHC Loos, MLF Martins, D de Jong, MC Lebre, M Tibben, JH Beijnen, ... International Journal of Pharmaceutics 650, 123708, 2024 | 1 | 2024 |
| P-glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Main Active Heroin Metabolites 6-monoacetylmorphine (6-MAM) and Morphine in Mice ML F. Martins, NHC Loos, M El Yattouti, L Offeringa, P Heydari, ... Pharmaceutical Research 40 (8), 1885-1899, 2023 | 1 | 2023 |
| The role of drug efflux and uptake transporters in the plasma pharmacokinetics and tissue disposition of morphine and its main metabolites MLF Martins, P Heydari, W Li, A Martínez-Chávez, M El Yattouti, ... Toxicology and Applied Pharmacology 490, 117040, 2024 | | 2024 |
| Neuroprotective action of a kyotorphin derivative in an animal model of Alzheimer's disease MLF Martins | | 2016 |
